Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin for IPA in COPD
NCT01499433Phase 4Unknown
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2012
- Primary completion
- Sep 2014
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of caspofungin in Invasive Pulmonary Aspergillosis (IPA), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Global response (clinical and microbiologic success) at 3 weeks. Status: unknown.
02
Drugs
caspofungin
03
Conditions
Invasive Pulmonary Aspergillosis (IPA)
Beyond the preview
Go deeper on NCT01499433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01499433.